04.09.2012 - The Bioindustry Association suggests to create a fund that allows Britons to invest in innovative small companies in their home region.
When an idea from France is worth considering in the UK it has to be indeed ground-breaking. London-based Bioindustry Association (BIA) published on 3 September a new report that proposes the creation of a so-called „Citizen’s Innovation Fund“ (CIF). The concept is based on the French „Fonds Communs de Placements dans l’Innovation“ (FCPI) that has raised over €6bn since 1997. The basic idea is to fuel funding of small companies by offering investors tax advantages that, according to BIA Chief Executive Officer Steve Bates, „would allow members of the public to put up to £15,000 a year into a fund for dragons’ den-style experts to invest in innovative companies – with a tax break if they keep their money invested for five years.“ By investing in local enterprises, the CIFs would improve the British public’s engagement in the economic development of their homeland.
The BIA estimates that £300m a year could be unlocked. The money would allow the companies to grow faster and pay taxes sooner than otherwise possible. The government’s expenditures would be levelled within three years and as a side effect over 1,500 new jobs could be created.
17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.
11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.
09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.
08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.
The LiposoFast-Basic produces unilamellar liposomes by the manual extrusion of a multilamellar liposome suspension through a polycarbonate membrane of defined pore size, using gas-tight, glass syringes. more